Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 4Recruiting 3Terminated 1Not yet recruiting 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

ALK Positive Non-small Cell Lung Cancer 1

Interventions

Specimen Handling 65Magnetic Resonance Spectroscopy 44Cyclophosphamide 32Carboplatin 31Gemcitabine 30Biopsy 28Cisplatin 25Bevacizumab 25Radiotherapy 24pembrolizumab 23Paclitaxel 23Standard of Care 22Oxaliplatin 22fludarabine 21Nivolumab 21Drug Therapy 21Capecitabine 21venetoclax 20Interviews as Topic 18Injections 17Radiosurgery 16Blood Specimen Collection 16toripalimab 15cemiplimab 15Dexamethasone 15Azacitidine 15tislelizumab 14Irinotecan 14Docetaxel 14anlotinib 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × lorlatinib × 90 days × Clear all
NCT07617337 2026-06-01

AQUA07 in Patients With ALK-Positive Non-Small Cell Lung Cancer

Chugai Pharmaceutical

Phase 1 Not yet recruiting
102 enrolled
Thoracic

ALK Positive Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡